

David Cuendet, MD
Rossella Sarro, MD
Laurent Merz, MD
Mayté Castro Jiménez,
MD
Philippe Maeder, MD
Renaud Du Pasquier, MD
Pinelopi Tsouni, MD

*Neurol Neuroimmunol
Neuroinflamm*
2017;4:e370; doi: 10.1212/
NXL.0000000000000370

AN UNUSUAL CASE OF MILIARY PML-IRIS IN AN HIV+ PATIENT

OPEN

A 45-year-old female patient recently diagnosed with HIV infection (CD4⁺ cell count 64 cells/mm³ and plasma HIV viral load 1.4×10^6 copies/mL at diagnosis) started antiretroviral therapy (ART). At the time, she presented with gastric cryptosporidiosis and an oral candidiasis, which subsided rapidly on treatment. One month after ART initiation, the patient noticed progressive generalized slowness, speech difficulty, and a slight weakness of her right arm and leg. She also reported headache, generalized fatigue, night sweats, and weight loss. She was admitted to the hospital 4 weeks after symptoms onset. The neurologic examination revealed psychomotor slowing, mild memory and executive dysfunction, meningeal signs, dysarthria, mild lower-limb ataxia, and right faciobrachial weakness (Medical Research Council grade 4). Generalized adenopathy and wasting syndrome were also identified. Brain MRI showed a pattern of multiple miliary-enhancing parenchymal nodules (1–4 mm in diameter) more marked in the brain stem and basal ganglia (figure, A–D).

CD4⁺ cell count was 89 cells/mm³ (11.8%), and plasma HIV viral load had dramatically dropped at 47 copies/mL. Serological testing revealed past exposure to *Toxoplasma gondii*, Epstein-Barr virus (EBV), and cytomegalovirus (CMV). *Cryptococcus neoformans* antigen and serologies for rubella virus, herpes simplex viruses (HSV) 1 and 2, varicella zoster virus (VZV), *Borrelia* sp, *Bartonella henselae*, and hepatitis B and C were negative. Serum *Treponema pallidum* hemagglutination assay and venereal disease research laboratory test (VDRL) were nonreactive. Peripheral blood flow cytometry showed no malignant cells. Antinuclear antibody (anticytoplasm) titers were positive (1/640), but C3 and C4 complement titers were within normal limits. Erythrocyte sedimentation rate was 110, and C-reactive protein was inferior to 2 mmol/L.


CSF examination did not reveal any leukocyte or erythrocyte; the protein content was within normal limits (431 mg/L); and the CSF-to-serum glucose ratio was 0.7. There was no intrathecal IgG synthesis. A quantitative PCR for JC virus (JCV) DNA was positive

in CSF at 965 copies/mL. All the following analyses performed in the CSF were negative or normal: cryptococcal antigen, bacterial, fungal, and acid-fast cultures; PCR for *Toxoplasma gondii*; CMV, HSV, VZV, and *Tropheryma whipplei*; VDRL; and cytology. CSF HIV viral load was not measured. Stool specimen analysis revealed no *Entamoeba histolytica*, *Giardia lamblia*, microsporidies, or *Cryptosporidium*.

The diagnosis of progressive multifocal encephalopathy (PML) was considered. However, because the radiologic findings were absolutely not typical for this disease, a stereotactic brain biopsy was performed. This examination showed diffuse and dense perivascular inflammatory infiltrate (figure, E), scattered atypical astrocytes with hyperchromatic nuclei (figure, F, arrowheads), and demyelination (figure, G). Immunohistochemistry showed CD3 underlining dense T-lymphocyte infiltration, mostly CD8⁺ and glial cells staining positive for JCV (figure, H–J). The diagnosis of PML in the setting of immune reconstitution inflammatory syndrome (IRIS) was established, and the patient was treated with CCR5 antagonist maraviroc with a favorable outcome. ART treatment was continued.

PML is typically associated with subcortical confluent nonenhancing lesions. However, rarely, PML may have a “miliary” presentation.¹ This form is characterized by enhancing punctuate lesions on brain MRI, which correspond, histopathologically, to a perivascular inflammation composed mostly of CD8⁺ T cells in contact with JCV-infected glial cells.² Such a punctuate pattern has been described in natalizumab-associated PML,³ but may be also seen in PML classically associated with some sort of immunosuppression, such as neurosarcoidosis or hematologic diseases.¹ A similar radiologic pattern was also reported in a patient with myelofibrosis exhibiting a rare mutation of the JCV genome.⁴ To the best of our knowledge, only one other case of miliary HIV-related PML has been reported so far in a patient who was initially diagnosed with EBV encephalitis.⁵

Our patient and the review of the literature suggest that miliary PML may occur at an early stage of JCV brain infection preceding the emergence of typical PML lesions.¹ In our case, the presence of a strong JCV-specific cellular immune response



T2 axial (A) showing diffuse hyperintensities in basal ganglia and centrum semiovale on both sides, T1 transverse (B) and sagittal (C and D) showing dilated enhancing perivascular spaces after gadolinium enhancement. Neuropathology: brain parenchyma showing diffuse and dense perivascular inflammatory infiltrate (E, hematoxylin and eosin [H&E]), scattered atypical astrocytes with hyperchromatic nuclei (F, H&E, arrowheads), and demyelination (G, Luxol fast blue). CD3 (H, immunohistochemistry [IHC]) outlines dense T-lymphocyte infiltration, mostly CD8⁺ (I, IHC). JC virus-infected oligodendrocytes (J, IHC, arrowheads) and bizarre astrocytes (J, IHC, arrow).

suggests that miliary PML represents a very early stage of unmasking PML-IRIS. In conclusion, this case illustrates that a miliary or punctate pattern on brain MRI should prompt clinicians to rule out PML.

From the Division of Neurology (D.C., M.C.J., R.D.P., P.T.), Department of Clinical Neurosciences, Department of Pathology (R.S.), Department of Infectious Diseases (L.M.), and Department of Radiology (P.M.), Lausanne University Hospital (CHUV), Switzerland.

Author contributions: D. Cuendet: acquired, analyzed, and drafted the content of this clinical reasoning including medical writing. P. Maeder and R. Sarro: acquired, analyzed, and drafted the content of the figure and their legends. L. Merz and M.C. Jiménez: revised the content of this manuscript. R. Du Pasquier: revised the manuscript for content and did the supervision of this case report. P. Tsouni: acquired, analyzed, and revised the content of this manuscript and did the supervision of this case report.

Study funding: No targeted funding reported.

Disclosure: D. Cuendet, R. Sarro, L. Merz, M.C. Jiménez, and P. Maeder report no disclosures. R. Du Pasquier served on the scientific advisory board for Biogen, Genzyme, Novartis; received travel funding and/or speaker honoraria from Sanofi and Genzyme; served on the editorial board for Journal of Neurovirology; and received research support from Swiss National Foundation, Swiss Society for Multiple Sclerosis, and Novartis. P. Tsouni reports no disclosures. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives

License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Received March 22, 2017. Accepted in final form April 10, 2017.

Correspondence to Dr. Tsouni: penelopsouni@gmail.com

- Hodel J, Darchis C, Outteryck O, et al. Punctate pattern: a promising imaging marker for the diagnosis of natalizumab-associated PML. *Neurology* 2016;66:1516–1521.
- Wattjes MP, Verhoeff L, Zentjens W, et al. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? *J Neurol Neurosurg Psychiatry* 2013;84:1176–1177.
- Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal encephalopathy. *Ann Neurol* 2012;72:779–787.
- Tallantyre EC, Paine SM, Sharp CP, Lowe JS, Gran B. Atypical progressive multifocal leukoencephalopathy associated with an unusual JC Polyomavirus mutation. *Arch Neurol* 2009;66:1021–1024.
- Gheuens S, Buggy BP, Tlomak W, Wüthrich C, Koralknik IJ. A game of viral hide and seek: miliary PML masquerading as EBV encephalitis in an HIV⁺ patient. *Clin Neurol Neurosurg* 2013;115:1861–1863.

Neurology[®] Neuroimmunology & Neuroinflammation

An unusual case of miliary PML-IRIS in an HIV+ patient

David Cuendet, Rossella Sarro, Laurent Merz, et al.

Neurol Neuroimmunol Neuroinflamm 2017;4;

DOI 10.1212/NXI.0000000000000370

This information is current as of June 14, 2017

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/4/4/e370.full.html
References	This article cites 5 articles, 1 of which you can access for free at: http://nn.neurology.org/content/4/4/e370.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Autoimmune diseases http://nn.neurology.org/cgi/collection/autoimmune_diseases HIV http://nn.neurology.org/cgi/collection/hiv MRI http://nn.neurology.org/cgi/collection/mri Post-infectious http://nn.neurology.org/cgi/collection/postinfectious_ Viral infections http://nn.neurology.org/cgi/collection/viral_infections
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.

